A NOTE FROM BEN - AUGUST 2012

Dear Industry Colleagues,

It is my privilege to update you on QPS’ continuous growth and global expansion. At QPS, we appreciate opportunities to work with our clients and interact with industry colleagues in the scientific community. We know we all have a common goal: to help develop medicines that will benefit patients worldwide.

I want to start by thanking all QPS employees for working so diligently to serve our clients’ needs globally. These are exciting, dynamic times for QPS. After experiencing a challenging period in our industry in 2009/2010, QPS made four acquisitions in 2010/2011! This growth has enabled us to offer our clients impressive global capability in Bioanalysis, Translational Medicine, Preclinical, Early Clinical, and Phase II - IV clinical services.

QPS now has access to significantly more opportunities than ever before. During 2011/2012, we pursued and won contracts that are being fulfilled through a synergy of services from multiple QPS sites around the world. QPS continues to recruit and hire high-quality employees to complement our experienced staff. Globally, QPS now comprises 900+ employees with a presence in four continents, nine countries and ten sites. In concert with our expansion, QPS is proud of and strives to maintain a friendly and caring company culture at all of our business sites.

It is with excitement and great pleasure that I announce QPS’ newest acquisition, JSW Life Sciences, which is headquartered in Grambach, Austria, in a state-of-the-art, environmentally-friendly, 2,638 square meter facility. Founded in 1999 by Dr. Manfred Windisch, JSW provides preclinical and clinical phase I – IV drug development services to pharmaceutical and biotech companies worldwide. JSW is highly experienced and established in both preclinical and clinical services, and specializes in preclinical services for central nervous system (CNS) diseases. JSW has developed its reputation over the past 13 years as a full service, high quality CRO and the leading specialist in CNS diseases including Alzheimer's, Parkinson's, Huntington’s, Stroke, Depression, Psychosis and Schizophrenia.

JSW’s reputation in the CNS field is further enhanced by its capabilities in preclinical efficacy studies including in vitro molecular and cellular analysis, proprietary in vivotransgenic mouse and rat models, and associated analytics. JSW’s clinical operations focus on complete clinical development from phase I – IV (mono- and multi-centric trials), including project planning, project management, trial monitoring, database management, data analysis, medical writing and regulatory affairs. Its Central and Eastern European (CEE) operations assure JSW’s customers a large patient population.

QPS’ preclinical and clinical service offerings are broadened by JSW’s:

  • Pharmacology capabilities, which fill gaps in QPS’ preclinical offerings and improve QPS’ ability to offer full-service IND-enabling studies
  • Proprietary ”transgenic models business” which enhances QPS’ overall scientific portfolio in the CNS area
  • Clinical division, which extends QPS Netherlands’ later-stage site-monitoring capability to most of Central and Eastern Europe, and provides additional project management capabilities

I am pleased and proud of QPS’ past accomplishments and want to underscore that QPS is well-positioned to achieve success and realize its corporate vision, which is:

  • QPS is a global leader in contract research.
  • QPS is known for quality, technical expertise, efficiency, and customer focus.
  • QPS is recognized for passionate and productive work which creates value for patients and customers, while creating opportunities for employees to grow and thrive.

QPS is committed to working hard every day to realize our vision of success, and to partnering with our clients to achieve our common goals.

Sincerely Yours,

Ben Chien, Ph.D.
QPS Founder, Chairman and CEO

back
top
20 years in pharma R&D navigation